Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. by Joimel, Ulrich et al.
Stimulation of angiogenesis resulting from cooperation
between macrophages and MDA-MB-231 breast cancer
cells: proposed molecular mechanism and effect of
tetrathiomolybdate.
Ulrich Joimel, Caroline Gest, Jeannette Soria, Linda-Louise Pritchard, Je´roˆme
Alexandre, Marc Laurent, Emmanuel Blot, Lionel Cazin, Jean-Pierre Vannier,
Re´mi Varin, et al.
To cite this version:
Ulrich Joimel, Caroline Gest, Jeannette Soria, Linda-Louise Pritchard, Je´roˆme Alexandre, et
al.. Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-
MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate..
BMC Cancer, BioMed Central, 2010, 10 (1), pp.375. <10.1186/1471-2407-10-375>. <inserm-
00617229>
HAL Id: inserm-00617229
http://www.hal.inserm.fr/inserm-00617229
Submitted on 26 Aug 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH ARTICLE Open Access
Stimulation of angiogenesis resulting from
cooperation between macrophages and MDA-
MB-231 breast cancer cells: proposed molecular
mechanism and effect of tetrathiomolybdate
Ulrich Joimel1*, Caroline Gest1, Jeannette Soria2,3, Linda-Louise Pritchard4, Jérôme Alexandre2,5, Marc Laurent1,
Emmanuel Blot1, Lionel Cazin1, Jean-Pierre Vannier1, Rémi Varin1, Hong Li1†, Claudine Soria1†
Abstract
Background: Infiltration by macrophages (M) indicates a poor prognosis in breast cancers, in particular by
inducing angiogenesis. Our study aimed 1) to investigate the mechanism by which cooperation between M and
aggressive breast cancer cells (MDA-MB-231) induces angiogenesis; 2) to examine the effect of tetrathiomolybdate
(TM) on this angiogenic activity.
Methods: M coincubated with MDA-MB-231 were used as a model to mimic the inflammatory
microenvironment. Angiogenesis induced by the culture media was tested in the chick chorioallantoic membrane
(CAM). M phenotype was evaluated by 1) expression of the M1 marker CD80, and secretion of interleukin 10 (IL-
10), an M2 marker; 2) capacity to secrete Tumour Necrosis Factor a (TNFa) when stimulated by lipopolysaccharide/
interferon g (LPS/IFNg); 3) ability to induce MDA-MB-231 apoptosis. To explore the molecular mechanisms involved,
cytokine profiles of conditioned media from MDA-MB-231, M and the coculture were characterised by an
antibody cytokine array. All experiments were carried out both in presence and in absence of TM.
Results: Incubation of M with MDA-MB-231 induced a pro-angiogenic effect in the CAM. It emerged that the
angiogenic activity of the coculture is due to the capacity of M to switch from M1 M towards M2, probably due
to an increase in Macrophage Colony Stimulating Factor. This M1-M2 switch was shown by a decreased expression
of CD80 upon LPS/IFNg stimulation, an increased secretion of IL-10, a decreased secretion of TNFa in response to
LPS/IFNg and an inability to potentiate apoptosis. At the molecular level, the angiogenic activity of the coculture
medium can be explained by the secretion of CXC chemokines/ELR+ and CC chemokines. Although TM did not
modify either the M2 phenotype in the coculture or the profile of the secreted chemokines, it did decrease the
angiogenic activity of the coculture medium, suggesting that TM inhibited angiogenic activity by interfering with
the endothelial cell signalling induced by these chemokines.
Conclusions: Cooperation between M and MDA-MB-231 transformed M1 M to an angiogenic, M2 phenotype,
attested by secretion of CXC chemokines/ELR+ and CC chemokines. TM inhibited this coculture-induced increase in
angiogenic activity, without affecting either M phenotype or cytokine secretion profiles.
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Background
It has become clear that analysis of tumour stroma is of
crucial importance to better understanding cancer pro-
gression. Cancer cell growth and invasion of surround-
ing tissues, as well as the metastatic process itself,
require the support of the cancer stroma.
Macrophages (M) form the major component of the
inflammatory infiltrate observed in tumours [1]. They
exhibit a distinct phenotype and are termed Tumour-
Associated Macrophages (TAM) [2]. Monocytes enter
tumours through blood vessels, and a number of
tumour-derived chemoattractants are thought to ensure
this ongoing recruitment [3,4]. This is also supported by
the observation that the levels of chemoattractant pro-
teins in tumours correlate positively with the numbers
of TAMs present in these tumours [5]. Classically, it has
been accepted that fully activated M have the potential
to inhibit tumour development. TAMs that express an
M1 phenotype are characterized by a proinflammatory
cytokine profile and expression of Major Histocompat-
ibility Complex molecules. They are capable of killing
tumour cells mainly by secreting inflammatory cytokines
such as Tumour Necrosis Factor a (TNFa). Although
associated with better prognosis, immune responses to a
tumour are often weak and not able to destroy the
tumour completely [6], suggesting that tumours have
developed mechanisms for escaping immune surveil-
lance. Further, the presence of M in breast cancer is
associated with a poor prognosis [7-10] due to the role
of TAMs as promoters of tumour progression and inva-
sion. Increasing evidence also indicates that TAMs
enhance angiogenesis, contributing to cancer cell prolif-
eration and dissemination [11-14]. This could explain
the positive relationship between high levels of TAMs
and breast cancer aggressiveness and their correlation
with high vessel density as reported in the literature
[15,16].
We have previously shown that the deleterious role
of M in cancer progression is due to the cooperation
of monocytes with cancer cells [17]. The modifications
of M functions in tumours could be explained by a
switch of M1 M to M2 M, which have protumoral
properties, including promotion of angiogenesis, matrix
remodelling and suppression of adaptive immunity
[18,19]. This indicates a functional plasticity and an in
situ M reprogramming. The biological mechanism for
this switch remains controversial. For Hagemann et al.
[20,21] and Greten et al. [22], the malignant epithelial
cancer cells drive nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-B) activation by
TAMs in a way that maintains their immunosuppressive
M2 phenotype. Consequently, the blockage of NF-B
might be expected to switch the M2 M to an M1 phe-
notype. Hence these studies would predict a potential
anti-tumour effect of NF-B inhibitors by the restora-
tion of M1 immunity, providing a cytotoxic activity.
However, the role of NF-B in this switch is contested
by others. Saccani et al. [23] and Bohuslav J et al. [24]
conversely proposed that during the M1 to M2 M
switch, an inactivation of NF-B occurs, explaining the
absence of TNFa production when M are stimulated
by lipopolysaccharide (LPS). This could be due to a
massive nuclear localization of the p50 NF-B protein
resulting in p50/p50 homodimers. Since the p50 homo-
dimers lack the transactivation domain, they compete
with the canonical p65/p50 heterodimers for the NF-B
binding sites on the inflammatory gene promoters,
thereby blocking p65/p50 promoter binding and gene
transcription.
Thus, although the relationship between inflammation
and cancer aggressivity is widely accepted, many of the
molecular and cellular mechanisms mediating this rela-
tionship remain unclear. The current study was
designed to determine the role of the cooperation
between M and the aggressive breast cancer cells
MDA-MB-231 in angiogenesis promotion. To elucidate
the mechanism, we mimicked the inflammatory tumour
environment by a coincubation of MDA-MB-231 cells
with M. Angiogenic activity of the coculture medium
was compared with the culture medium from both
MDA-MB-231 and M cultured individually in the
chick chorioallantoic membrane (CAM) model.
We first determined that the cooperation between M
and cancer cells led to a switch of M1 M to the M2
phenotype, known to be angiogenic. Then we explored
the potential molecular mechanisms responsible for this
angiogenic activity. Results indicate that a wide reper-
toire of chemokines (CXC-ELR+ and CC-chemokines)
may drive the neoangiogenesis induced by the coopera-
tive effects of cancer cells and M. Finally, tetrathiomo-
lybdate (TM), an oral copper-depleting agent that has
been shown to inhibit tumour-cell-induced angiogenesis
[25-27] was tested in our model of cooperation between
M and MDA-MB-231. This was important to check
because the effect of TM has not previously been ana-
lysed in this context of inflammation in cancers.
Methods
Cell Culture and Reagents
MDA-MB-231 cells were maintained in RPMI 1640
medium (Eurobio) supplemented with 100 U/ml penicil-
lin (Eurobio), 100 μg/ml streptomycin (Eurobio), 2 mM
L-glutamine (Eurobio) and 10% heat-inactivated foetal
calf serum (FCS, Eurobio). All incubations were carried
out in a humidified atmosphere at 37°C and 5% CO2.
LPS was purchased from Sigma-Aldrich and human
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recombinant interferon g (IFNg) from R&D Systems.
TM is a gift from Professor F. Sécheresse, Institut Lavoi-
sier (CNRS UMR 8637, Versailles).
Preparation of M
Human monocytes were isolated as described [28].
Briefly, monocytes were isolated from buffy coats using
lymphocyte separation medium (Eurobio). Peripheral
blood mononuclear cells were washed three times with
phosphate-buffered saline (PBS, Eurobio) and allowed
to adhere to Primaria™ cell culture flasks (Becton
Dickinson) for 1 h at 37°C. Nonadherent cells were
removed. Monocytes were then incubated in AIM-V®
medium (Gibco) for 7 days, as recommended for long-
term cultivation of human M [29]. Medium was
changed, and nonadherent cells discarded, every 2 days.
We found that all monocyte-derived cells isolated this
way express the marker CD14, which can be used to
distinguish them from cancer cells.
Coculture of MDA-MB-231 cancer cells with M
Primary human monocyte-derived M were detached
using a 30 min incubation with Accutase™ enzyme cell
detachment medium (eBioscience). 25 × 103 MDA-MB-
231 cells were plated in 96-well culture dishes (7.8 × 104
cells/cm2) and allowed to adhere for 6 h at 37°C. More
than 95% of the cells adhered to the wells. Then the same
number of M was added, and cocultures were main-
tained for 5 days in RPMI 1640 medium supplemented
with 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM
L-glutamine and 10% heat-inactivated FCS. Spent med-
ium was replaced by fresh medium every 24 h. Control
groups consisted of 2.5 × 104 MDA-MB-231 alone and of
2.5 × 104 M alone cultured under the same conditions.
Where indicated, after 5 days of incubation the cultures
were treated with 1 μg/ml LPS and 5 ng/ml IFNg for 24 h
to activate the M. Cultures approached but did not
reach confluence during this time.
In vivo angiogenesis assays using the CAM model
All MDA-MB-231 and M cultures were carried out
both in presence and in absence of 5 μM TM (final con-
centration). The CAM assay was performed as described
by others [30], using conditioned media collected from
the cocultures and from individual MDA-MB-231 and
M cultures during the final 24 h of incubation, and
stored at -80°C until use. Briefly, fertilized chick eggs
(White Leghorn) purchased from the Ferme Avicole
HAAS, Kaltenhouse, France, were incubated for 4 days at
37°C and a relative humidity of 80%. During this period,
the eggs were positioned with the pointed end down and
rotated several times. After this incubation, the shells
were cracked open and the embryo eggs placed in plastic
culture dishes (Merck-Eurolab) according to an
established shell-less culture technique exposing the
CAM to a direct access for experimental manipulation.
At day 6 of embryonic development, angiogenic areas
were circled with a silicon ring (Weber Métaux). To
induce angiogenesis, 33 μl of either the culture medium
to be tested or recombinant human basic Fibroblast
Growth Factor (bFGF) (R&D Systems) (positive control)
were next placed inside the rings on successive days for 3
days. Treated areas were photographed and the extent of
angiogenesis evaluated 24 h after the last treatment: the
total number of vessels which had sprouted from the pri-
mary vessels of the CAM and the total length of the
neoangiogenesis were determined using Saisam software
(Microvision Instruments).
Characterization of M by immunofluorescence analysis
Cultures and cocultures were carried out as described
above, except that each cell population was seeded into
8-well Lab-Tek™ II -CC2™ chambers (Nunc) at a density
of 5.7 × 104 cells/cm2. Five days later, all cultures were
treated with 1 μg/ml LPS and 5 ng/ml IFNg for 24 h
before washing and labelling. M were identified by
examining the expression of CD14, which is a differen-
tiation antigen expressed by monocytes and M, and of
CD80, which is a marker of M1 M [31]. Expression of
these molecules was evaluated by immunofluorescence
both before and after activation with 1 μg/ml LPS and
5 ng/ml IFNg for 24 h. Breast cancer cells were identi-
fied by cytokeratin 19 (CK 19) expression.
Briefly, cells were fixed for 15 min in 4% paraformalde-
hyde/PBS, then washed and incubated for 30 minutes
with PBS containing 5% bovine serum albumin (BSA).
For M identification, samples were incubated with rab-
bit anti-CD14 polyclonal antibodies at 2 μg/ml (Abcam)
or biotinylated monoclonal anti-human CD80 at 2.5 μg/ml
(Ancell Corporation) for 60 min at room temperature. For
identification of breast cancer cells, they were then washed
in PBS/1% BSA before incubation with monoclonal anti-
human CK 19 (Dako) diluted 1:50 in PBS/1% BSA. Follow-
ing washing in PBS with 1% BSA, cells were incubated
with, respectively, DyLight 488™-conjugated goat anti-rab-
bit IgG secondary antibody or DyLight 549™-conjugated
streptavidin (Thermoscientific) for 60 minutes at room
temperature or else Texas-Red labelled goat anti-mouse Ig
diluted 1:2000 (AbD Serotec). After final washing, cover
slips were mounted with mounting medium (Immunocon-
cepts). Samples were photographed using a Leica DM
5500B. Controls prepared without primary antibodies
confirmed that, under the conditions used, background
fluorescence was negligible.
Ability of LPS + IFNg-activated M to secrete TNFa
For these experiments, cells cultured as described above
were activated on day 5 with 1 μg/ml LPS and 5 ng/ml
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IFNg for 24 h. These 24-h culture supernatants were
then collected and tested for TNFa. Concentrations of
TNFa within the supernatants were determined by
human TNFa Enzyme-Linked Immunosorbent Assay
(ELISA) Ready-Set-go! (eBioscience) using the standard
protocol given by the manufacturer, and compared to
those of supernatants from non-activated control cul-
tures. TNFa concentrations are expressed in pg/ml. 3
independent experiments were carried out both in pre-
sence and in absence of 5 μM TM.
Ability of M to induce apoptosis in cocultures
M and MDA-MB-231 cells were cultured separately
and together (coculture) as indicated above for 5 days,
in presence or absence of 5 μM TM. Apoptosis was
measured using the ELISAPLUS cell death detection kit
(Roche Diagnostics). Briefly, apoptosis-induced Desoxy-
Ribonucleic Acid (DNA) fragmentation was evaluated by
quantifying the histone-complexed DNA fragments
(nucleosomes) found in the cytoplasm, as indicated by
the manufacturer. Results are expressed as the adjusted
absorbance, A405 minus A490.
Ability of M to secrete interleukin 10 (IL-10)
For these experiments, supernatants were harvested on
day 5 from cells cultured as described above. These 24-h
culture supernatants were then tested for IL-10. Concen-
trations of IL-10 within the supernatants were determined
by human IL-10 ELISA Ready-Set-go! (eBioscience) using
the standard protocol given by the manufacturer. IL-10
concentrations are expressed in pg/ml. 3 independent
experiments were carried out both in presence and in
absence of 5 μM TM.
Cytokine array
The Human Cytokine Antibody Array III kit (RayBio-
tech) was used to evaluate 42 different cytokines:
Epithelial Neutrophil-Activating peptide-78 (ENA-78),
Granulocyte Colony-Stimulating Factor (GCSF), Granu-
locyte-Macrophage Colony Stimulating Factor (GM-
CSF), Growth related oncoprotein (GRO), GROa, I-309,
IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12 p40p70, IL-13, IL-15, IFNg, Monocyte Che-
motactic Protein-1 (MCP-1), MCP-2, MCP-3, Macro-
phage Colony Stimulating Factor (MCSF), Macrophage-
Derived Chemokine (MDC), Monokine induced by IFNg
(MIG), Macrophage Inflammatory Protein-1a (MIP-1a),
Regulated on Activation Normal T cell Expressed and
Secreted (RANTES), human Stem Cell Factor (SCF),
Stromal-Derived Factor-1 (SDF-1), Thymus and Activa-
tion-Regulated Chemokine (TARC), Transforming
Growth Factor-b1 (TGF-b1), TNFa, TNF-b, Epidermal
Growth Factor (EGF), Insulin-like Growth Factor-I
(IGF-I), Angiogenin, Oncostatin M, Thrombopoietin,
Vascular Endothelial Growth Factor (VEGF), Platelet-
Derived Growth Factor-BB (PDGF BB) and Leptin. GRO
detects CXC Ligand 1 (CXCL1), CXCL2 and CXCL3;
GROa detects only CXCL1. VEGF detects VEGF-165
and VEGF-121.
Briefly, 1 ml of undiluted supernatants harvested on
day 5 from cells cultured as described above were incu-
bated with arrayed antibody membranes, which were
then exposed to the specific biotin-antibody cocktail,
following the manufacturer’s instructions. Signals were
detected using labelled streptavidin by exposure on X-
ray films. The relative amount of each cytokine present
in the coculture medium is presented as the fold
increase of the spot intensity in the coculture medium
as compared to that of the culture medium of either
M cultured alone (for cytokines which were not
secreted by MDA-MB-231), or MDA-MB-231 cultured
alone (for cytokines which were not secreted by M), or
else the sum of the two (for cytokines secreted sepa-
rately by both M and MDA-MB-231 when cultured
individually). The area density of the spots was evalu-
ated using imageJ (written in Java) which was down-
loaded from the National Centre for Biotechnology
Information. Signals were normalized against the posi-
tive controls across membranes. Cytokine array experi-
ments were carried out in duplicate.
Results
Angiogenic activity of the M + MDA-MB-231 coculture
medium in the CAM
We found that the conditioned medium from cocultures
of M + MDA-MB-231 induced a more potent angio-
genic response in the CAM than that induced by condi-
tioned medium from either M or MDA-MB-231 cells
cultured alone, as shown by the formation of a second-
ary dense thin capillary network only after treatment
with coculture medium (Figure 1A). Indeed, both the
number and the cumulative length of the capillaries that
sprouted from CAM vessels were significantly increased
by the coculture medium (Figure 1-B) (p < 0.05). The
positive control was bFGF.
Cell densities on day 0 and after 5 days of culture (day 5)
When plating the cells on day 0, more than 95% were
adherent (both cancer cells and M). We next deter-
mined the relative proportions of the two cell types in
the coculture after 5 days, because MDA-MB-231 is a
cell line which proliferates in culture, whereas M,
which are primary cells, do not. We found that in
5 days the number of MDA-MB-231 increased 5.3-fold
(standard error of the mean (SEM), ± 0.35) (not
shown). In contrast, M numbers did not change dur-
ing the 5 days of incubation, and fewer than 10% were
found detached, floating in the supernatants. After the
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5 days of coculture, the ratio of CK 19+ (cancer cells)
to M was also determined. It was found that 15% of
the cells were M, and 85% MDA-MB-231 (not
shown).
Modifications of M phenotype induced by coculture
Because the switch of M1 M to the M2 phenotype is
known to induce angiogenesis, we investigated the pos-
sibility of an M1-M2 switch when M were coincubated
with MDA-MB-231 cells. Immunolabelling of M cul-
tured in presence or absence of MDA-MB-231 showed
that all cells isolated as M are CD14 positive. These
CD14+ cells were found to express CD80 only when
activated by LPS/IFNg, indicating that activation could
stimulate them to differentiate towards an M1 pheno-
type. However, in the cocultures of M with MDA-
MB-231 cells, expression of CD80 by these activated
M was lost (Figure 2).
Figure 1 Effect of the cooperation between M and MDA-MB-231 cells on vascularisation of the CAM. MDA-MB-231 cells were seeded at
a density of 7.8 × 104 cells/cm2, with (coculture) or without the same number of M. Spent medium was replaced by fresh medium every day.
After 5 days of incubation, the conditioned media corresponding to the final 24 h of culture were tested for their angiogenic activity as follows:
each day, for 3 days, 33 μL of these media were introduced into silicon rings placed on CAMs from 6-day-old chick embryos. bFGF (25 ng/ml)
was used as positive control. Panel A: Treated areas were photographed 24 h after the last treatment. Note the increase in the CAM of a denser
secondary capillary network induced by the coculture medium, in comparison to that induced by conditioned medium from either MDA-MB-231
or M cultured alone. This secondary capillary network was inhibited by the addition of 5 μM TM during the coculture. Panel B: total number of
vessels that sprouted from the primary vessels of the CAM and total length of the neoangiogenesis. Mean of 3 independent experiments ± SEM.
* p < 0.05, Mann-Whitney U test.
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Figure 2 Immunolabelling of M by the monocyte/M marker CD14 and the M1 M marker CD80. M were seeded at a density of 5.7 ×
104 cells/cm 2, with (coculture) or without the same number of MDA-MB-231 cells. In each case, the culture medium was replaced daily. 5 days
later, all cultures were treated with 1 μg/ml LPS and 5 ng/ml IFNg for 24 h before washing and labelling. CD14 fluorescent labelling is green,
CD80 is red. Panel A: without TM, it can be seen that CD80 was expressed on activated M cultured alone and was not detectable on M in
the cocultures. Panel B: in presence of TM, no CD80-positive cells were found in any of the cultures.
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Effects of coculture on apoptotic activity, TNFa and IL-10
secretion
Without stimulation, M did not secrete detectable
amounts of TNFa. In contrast, as shown in Figure 3,
panel A, M activated by LPS/IFNg secreted a large
amount of TNFa. However, when these M were cocul-
tured with MDA-MB-231, a decreased secretion of
TNFa was observed (180 pg/ml in the coculture med-
ium versus 400 pg/ml in the M culture). This reduc-
tion of TNFa secretion by activated M is indicative of
a change in M phenotype from M1 to M2.
We also found that the coculture of M with cancer
cells did not potentiate the apoptotic activity of the M.
Indeed, as shown in Figure 4, panel A, the apoptosis
index measured in the coculture was equivalent to the
sum of the index measured in cultures of MDA-MB-231
alone plus that of M alone.
All these results suggest that M incubated with
MDA-MB 231 lose their M1 phenotype. Furthermore, a
switch toward the M2 phenotype is suggested by the
cooperation of M with MDA-MB-231, because the
secretion of IL-10 increased approximately twofold in
the coculture medium, compared to medium from M
cultured alone (Figure 5).
Molecular mechanism underlying the angiogenic activity
induced by the coculture medium
To explore the molecular mechanism responsible for the
angiogenic activity that arises from the cooperation
between M and cancer cells, we used an antibody-
cytokine array to analyse the secretion of cytokines and
chemokines. Results of this analysis (shown in Figure 6
and Table 1) revealed an increase in the coculture med-
ium, in comparison to the conditioned medium of both
M alone and MDA-MB-231 alone, of the following
mediators: CXC chemokines with an ELR motif, chemo-
kines that are known to be angiogenic (such as GRO,
GROa, ENA-78 and IL-8) and chemoattractant chemo-
kines, such as MCP-1 and MCP-3, that can lead to a
Figure 3 Secretion of TNFa into the culture medium of LPS
and IFNg-treated M, MDA-MB-231 and cocultures. Cultures
were incubated in the absence (A) or presence (B) of 5 μM TM, the
corresponding medium being renewed daily. In all cases, cells were
stimulated on day 5 with 1 μg/ml LPS and 5 ng/ml IFNg for 24 h.
Supernatants from these stimulated M, MDA-MB-231 and
cocultures were then tested for the presence of TNFa by ELISA.
Mean ± SEM of 3 independent experiments. * p < 0.05 between
M and coculture without TM; p < 0.01 between M without TM
and M with TM; p < 0.05 between coculture without and with TM.
Mann-Whitney test. TNFa was not detected in the supernatants of
non-activated cells, as also observed by cytokine array.
Figure 4 Apoptosis of M, MDA-MB-231 breast cancer cells,
and coculture cells. Cells were incubated for 5 days in the
absence (A) or presence (B) of TM (5 μM, final concentration), the
corresponding medium being renewed daily. Cell Death Detection
ELISA PLUS enzyme immunoassay (Roche Applied Science) was
used for the quantitative in vitro determination of cytoplasmic
histone-associated DNA fragments (mono- and oligonucleosomes)
in the cytoplasmic fractions of cells from these 5-day cultures. The
results are expressed as the absorbance at 405 nm minus the
absorbance at 492 nm. The apoptosis index measured in the
coculture was equivalent to the sum of the index measured in
cultures of MDA-MB-231 alone plus that of M alone. Mean ± SEM
of 3 independent experiments.
Figure 5 IL-10 secretion by M cultured in the absence or
presence of MDA-MB-231. Cells were incubated for 5 days in the
absence (A) or presence (B) of TM (5 μM, final concentration), the
corresponding medium being renewed daily; then culture media
corresponding to the final 24 h of incubation were tested for IL-10
by ELISA. No IL-10 was detected in medium from MDA-MB-231
cultured alone. Mean ± SEM of 3 independent experiments. * p <
0.05 between M without TM and coculture without TM; p < 0.05
between M without TM and M with TM.
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positive feed-back. An increased secretion of M-CSF was
also found and could be responsible for the switch from
M1 to M2. Fold changes of cytokine levels in the cocul-
ture medium as compared to culture medium of M,
MDA-MB-231 or the sum of M + MDA-MB-231 cul-
tured separately are presented in Table 2.
A faint spot indicating a low level of IL-10 production
was also observed in the coculture medium, which cor-
roborates the ELISA results suggesting that M in the
coculture acquired the M2 phenotype.
Effect of TM on the angiogenic activity induced by the
coculture
As shown in Figure 1, panels A and B, TM inhibited the
angiogenesis that was induced in the CAM by the cocul-
ture medium: both the total number of sprouting vessels
and the cumulative length of those vessels induced by
TM-containing coculture medium were similar to those
measured with conditioned medium from either mono-
cytes or MDA-MB-231 cells cultured separately in the
absence of TM. The observed difference in the effects of
coculturing the cells in presence versus absence of TM
is highly significant.
We next analysed the mechanism by which TM
inhibited the angiogenic activity of the coculture med-
ium. Because the M2 M phenotype was found to be
causally implicated in the angiogenic activity of the
coculture medium, we first hypothesized that TM
should be able to inhibit the M1-M2 switch observed
during the coculture. However, TM did not elicit a
change from M2 to M1 phenotype, as shown by the
following results: 1) in the coculture medium, whether
in the absence or in the presence of TM, CD14+ M
activated by LPS/IFNg failed to express CD80; and
what’s more, the expression of CD80 on M cultured
alone was prevented by the addition of TM to the cul-
ture medium, as shown in Figure 2A and 2B. 2) TM
inhibited by 80% the secretion of TNFa in LPS/IFNg-
stimulated M cultured either alone or with MDA-
MB-231, suggestive of an M2 phenotype (Figure 3).
Likewise, TM did not potentiate the apoptotic activity
in the coculture, where the apoptosis level was equiva-
lent to the sum of the levels seen in the individual cul-
tures: MDA-MB-231 alone plus M alone (Figure 4A
and 4B). These results indicate that TM does not
act by “reversing” the M phenotype (M2 to M1),
Figure 6 Cytokines secreted by M, by MDA-MB-231 cells and by the coculture. The assay was performed after 5 days of culture in the
absence (A) or presence (B) of 5 μM TM (final concentration), the corresponding medium being renewed daily. Culture supernatants
corresponding to the final 24 h of incubation were then collected and assayed for cytokine production using the Human Cytokine Antibody
Array III kit (RayBiotech). Ellipses indicate the coordinates of the secreted cytokines and chemokines. Films were developed from array
membranes following incubation with supernatants from either M cultures, MDA-MB-231 cells or the coculture. Positive controls are located at
positions A1, A2, D12. Negative controls are located at positions A3, A4 and D11. This experiment was repeated once with similar results.
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consistent with our observation that IL-10 secretion
was increased in TM-treated M (Figure 5).
Finally, we also tested the action of TM on the secre-
tion of cytokines and chemokines that is induced by the
cooperation between cancer cells and M. No changes
were observed when TM was added during the cocul-
ture (Figure 6, comparison between panel A without
TM and panel B in the presence of TM). The ratio of
cytokines secreted in the presence of TM in comparison
to its absence did not vary, as the fold change was
between 0.85 and 1.15.
Discussion
M constitute the most abundant immune cell popula-
tion present in the tumour microenvironment [1]. In
many cancers, including breast cancers, it is now widely
accepted that the presence of M is associated with a
poor prognosis. An increase in angiogenesis has been
considered to be one of the major causes of the deleter-
ious effect of M in tumours. For example, the density
of blood microvessels correlates with the extent of M
infiltration in breast cancer [11]; hence we hypothesized
that there was a cooperation between M and cancer
cells to induce this angiogenic process. We therefore
developed a model which mimics this cooperation by
Table 1 Modifications of chemokines induced by coculturing M with MDA-MB-231 cells
Chemokine Expressed
in
Overexpressed in
coculture
Family Function
M MDA
ENA 78
(CXCL5)
- - + CXC chemokine with
ELR motif
- Pro-angiogenic activity
- Neutrophil chemotaxis
- Monocyte migration
GM-CSF
(CSF2)
- + + Growth factor - Stimulates stem cells to produce granulocytes and monocytes
- Enhances monocytic migration via RhoA and integrin activation, and
via MMP expression
GRO (CXCL1,
2, 3)
+ + + CXC chemokine with
ELR motif
- Angiogenic activity
- Increased migration of PBMC/monocytes
GROa
(CXCL1)
- + + CXC chemokine with
ELR motif
- Angiogenic activity
- Increased migration of PBMC/monocytes
IL-6 - + + Inflammatory cytokine - Inflammatory cytokine with a well-documented role in cancer
- Recruitment of myelo-monocytes
IL-8 (CXCL8) + + + CXC chemokine with
ELR motif
- Migration of neutrophils
- Important role in tumour growth, angiogenesis, and metastasis
IL-10 - - + - Anti-inflammatory
cytokine
- Anti-inflammatory cytokine produced by M2 M
MCP-1
(CCL2)
+ - + CC chemokine - Recruitment of monocytes to sites of injury
MCP-3
(CCL7)
- - + CC chemokine - Inflammatory cytokine
MCSF (CSF1) - - + Growth factor - Facilitates monocyte survival, monocyte-to- M conversion, M
proliferation, M1 to M2 switch
MDC (CCL22) - - + CC chemokine -Chemotactic for monocytes
Table 2 Fold increase in cytokine secretion by coculture
of monocytes and MDA-MB-231, as compared to the
secretion by the two types of cells cultured separately
Cytokines Fold change
Group 1: cytokines secreted by M and not by MDA-MB-231:
Ratio coculture medium/M medium
MCP-1 1.45
Group 2: cytokines secreted by MDA-MB-231 and not by M
Ratio: coculture medium/MDA-MB-231 medium
GM-CSF 2.82
Groa 2.96
IL-6 2.68
Group 3: cytokines secreted by both M and MDA-MB-231
Ratio coculture/(M medium cultured separately + MDA-MB-231
medium cultured separately)
Gro 1.80
IL-8 2.35
Group 4: cytokines secreted only in the coculture medium
ENA-78
IL-10
MCP-3
In every case, the difference of spot intensity between duplicate
determinations was <10%. The mean of the 4 spots (2 membranes × 2 spots
per membrane) was used for determining the intensity of expression of each
cytokine.
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culturing M in vitro with the aggressive breast cancer
cells MDA-MB-231, analysed the consequences of this
cooperation, and investigated the molecular mechanism
mediating this angiogenic pathway. The M population
we tested was derived from blood monocytes and thus,
at least theoretically, might be anticipated to contain
some dendritic cells as well. Although we do not for-
mally exclude this possibility, our protocol for M pre-
paration does not favour differentiation into dendritic
cells. Indeed, neither the classical stimuli for dendritic
cell differentiation (IL4 plus GM-CSF [32,33]) nor more
recently reported contributory agents (IFNa, TNFa, IL-
15, thymic stromal lymphopoietin, Toll-like receptor
ligands [34]) were present during the 7-day culture per-
iod used to prepare M for testing. Removal of nonad-
herent cells during M generation further disfavours
dendritic cell differentiation, given that immature den-
dritic cells have been shown to be nonadherent cells
[35]. Moreover, MDA-MB-231 cells secrete IL-6 (Table
1), which is known to switch the differentiation of
monocytes from dendritic cells to M [36].
We found that the coculture medium induced greater
angiogenic activity than did the culture medium of
either M or MDA-MB-231 alone in the CAM model;
this enhanced angiogenic activity was evidenced by the
formation of a secondary capillary network in the CAM
with increases in both total number of capillaries and
total length of sprouted vessels. The increased angiogen-
esis was still seen when coculture medium was diluted
1:2 in order to normalize for the number of cells partici-
pating in the secretion of angiogenic factors (not
shown).
Next, we confirmed that the coculture of M with
MDA-MB-231 cells induced a switch of M1 M to an
M2 phenotype as shown 1) by the great reduction of
CD80 expression under stimulating conditions using
LPS and IFNg on CD14 positive cells (M) - the fact
that LPS markedly potentiated the expression of CD80
by M has also been observed by Foss et al. [37], 2) by
the reduction of TNFa secretion by LPS + IFNg acti-
vated M, suggestive of a reduction in the number of
M1 M during the coculture, and 3) by the increased
secretion of IL-10 into the coculture medium, pointing
to a switch toward an M2 phenotype. Interestingly, this
switch occurred despite the fact that, as shown by the
antibody cytokine array, MDA-MB-231 cultured alone
produce IL-6, which is an inflammatory cytokine (Figure
4). The M2 phenotype in our model was also character-
ized by its functional properties: a weak killing activity,
and an increase in angiogenesis in the CAM model.
Our results are in good agreement with a number of
studies showing that TAMs, which exhibit a predomi-
nantly M2-like phenotype [7], can elicit increased angio-
genic activity. However, the molecular mechanism
responsible for this angiogenic activity was not totally
elucidated. To address the molecular mechanism of the
angiogenesis pathway, we investigated the production of
pro-inflammatory chemokines and cytokines in cocul-
tures of MDA-MB-231 cells and M, in comparison to
the secretion by MDA-MB-231 or M cultured sepa-
rately. Our data (Figure 6 and Table 1) show that the
coculture medium contains a number of potent angio-
genic factors, as detected by a cytokine-antibodies array.
Among the cytokines that are secreted in large amounts
into the coculture medium in comparison with the cul-
ture medium of resting M or of MDA-MB-231, we
observed a great increase in CXC chemokines with the
three amino acids (Glu-Leu-Arg/ELR) immediately
amino-terminal to the CXC motif (ELR+), which are
known to be pro-angiogenic [38]. In particular, an
important secretion of the GRO chemokines CXCL1/
GROa, CXCL2/GROb, CXCL3/GROg, as well as
CXCL5/ENA-78 and CXCL8/IL-8 was noted. All these
chemokines play a significant role in mediating angio-
genic activity during tumourigenesis in a variety of can-
cers [39-44] and have been shown to be of great
importance in tumour progression [45,46].
Interestingly, in addition to their angiogenic activity, it
has been reported that these chemokines also play a
role in monocyte recruitment in inflammation, since the
blood monocytes express chemokine receptors, includ-
ing CXCR2. Besides other functions, the interactions of
these receptors with their chemokines induce monocyte
arrest and transmigration through the endothelium,
which is one of the earliest steps in monocyte recruit-
ment, thereby efficiently regulating inflammation [47].
Therefore our data are suggestive of an autocrine loop,
because these chemokines are secreted by M in coop-
eration with cancer cells, and they also participate in
monocyte recruitment.
In addition, ENA-78 was reported to be an attractant
for neutrophils [48], which can also be involved in
tumour growth and metastasis [49].
An increase in the proinflammatory cytokine IL-6 was
also observed in the coculture medium, whereas a
decrease in the secretion of this cytokine would have
been expected due to the M2 phenotype of the M in
the coculture. This can be explained by the observation
of a constitutive secretion of IL-6 by the MDA-MB-231
cells, which could be responsible for an autocrine loop
for IL-6 secretion, as has been proposed for colon can-
cer [50]. In other words, the observed increase in IL-6
secretion in the cocultures may be produced by the can-
cer cells themselves.
Our antibody array data also indicated an increase in
M-CSF concentration in the coculture medium in com-
parison to the conditioned media from both M alone
and MDA-MB-231 alone. This increased secretion could
Joimel et al. BMC Cancer 2010, 10:375
http://www.biomedcentral.com/1471-2407/10/375
Page 10 of 13
elicit neovascularisation in breast cancer [5,12] and
could also contribute to the M1 to M2 switch, since M-
CSF-treated monocytes express a substantial part of the
M2 transcriptome [51].
We next investigated the effect of TM on the angio-
genesis induced by the cooperation between M and
the MDA-MB-231 cancer cells. Several studies empha-
size that TM reduces the angiogenic activity induced by
tumours [52-58], which is why TM has been proposed
in the therapy of cancers. However, the effect of TM
has not previously been tested when cancer cells are
incubated with M, which represents a more physiologi-
cal context: cancer associated with inflammation. We
firstly demonstrated that the action of TM cannot be
explained by a reversion of the angiogenic M pheno-
type (M2 to M1), since CD80 was not detected on cells
cultured in presence of TM. We also determined that
the addition of TM led to a reduction of LPS/IFNg-
induced TNFa secretion (decrease of more than 80%)
and an increase of IL-10 secretion in cocultured cells,
and did not increase the apoptotic potential of M. Pan
et al. [52] have proposed that TM inhibits angiogenesis
through suppression of the NF-B signalling cascade.
Given that TNFa secretion is NF-B dependent, our
TNFa results (Figure 3) are consistent with this inter-
pretation, and seem to indicate that TM, like the cocul-
ture, induces a switch from M1 to M2. They also
suggest that defective activation of NF-B could lead to
an M2 phenotype.
Finally, we show that, in our model, TM, which inhi-
bits the angiogenic activity of the coculture medium,
does not modify the secretion of cytokines and chemo-
kines that is induced by the coculture. Therefore, we
rather propose that TM blocks the cell signalling
induced by the action of angiogenic chemokines on
endothelial cells. This would be in good agreement with
the studies of Donate et al. [26] and Juarez et al. [59],
who showed that TM attenuates angiogenesis through
the inhibition of superoxide dismutase.
Conclusions
In summary, based on the results and rationale pre-
sented here, we conclude that the cooperation between
M and the aggressive breast cancer cells MDA-
MB-231 transformed M1 M to an angiogenic, M2 phe-
notype. This coculture-induced increase in angiogenic
activity, attested by an increased secretion of CXC che-
mokines, was found to be inhibited by TM. However,
TM did not modify the cytokine secretion profile, which
suggests that the TM-mediated anti-angiogenic activity
may be due to defective cell signalling by these angio-
genic chemokines at the level of their endothelial cell
targets.
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